GlassScriptPhysician profile
Dale Ching
NPI 1427004282
$2,916.81
in general payments reported to CMS, 2019-2025
18 companies · $575 in 2025
The $575 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $266 · 2021: $383 · 2022: $286 · 2023: $259 · 2024: $461 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $740.68 | 2019-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb Americas INC. | $549.11 | 2022-2025 | Infuse, Infuse Multifocal, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $319.10 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $224.16 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $182.83 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $150.57 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $125.68 | 2019-2022 | |
| Abbvie INC. | $104.65 | 2022-2024 | |
| Astellas Pharma US INC | $97.20 | 2024 | Izervay |
| Glaukos Corporation | $76.17 | 2021 | |
| Oyster Point Pharma, INC. | $67.21 | 2022-2024 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $57.23 | 2025 | Xdemvy |
| Coopervision INC. | $49.57 | 2019-2024 | Clariti Contact Lens |
| Optos, INC. | $47.45 | 2019 | |
| Shire North American Group INC | $47.33 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.22 | 2021 | |
| Kala Pharmaceuticals, INC. | $23.25 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Ching listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.